<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00630734</url>
  </required_header>
  <id_info>
    <org_study_id>07-0272</org_study_id>
    <secondary_id>TMC114HIV4003</secondary_id>
    <nct_id>NCT00630734</nct_id>
  </id_info>
  <brief_title>Genetic Predictors of Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin</brief_title>
  <official_title>Genetic Predictors of Pharmacokinetic Variability in the Drug-drug Interaction Between Darunavir/Ritonavir and Pravastatin: the Role of SLCO1B1 Polymorphisms.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Colorado, Denver</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tibotec Therapeutics, a Division of Ortho Biotech Products, L.P., USA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Colorado, Denver</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pravastatin (Pravachol) is approved by the Food and Drug Administration (FDA) and is used to
      treat high cholesterol. Darunavir (Prezista) and ritonavir (Norvir) are approved by the Food
      and Drug Administration (FDA) to treat HIV infection. When darunavir and ritonavir are given
      with pravastatin, they can increase the blood levels of pravastatin. The degree of this
      interaction varies from person to person. The way that darunavir and ritonavir interact with
      pravastatin may be affected by a person's genetic make-up. Genetic factors (or DNA) are those
      that people are born with and that make each person unique. Genetic differences are the
      reason why one person's body traits such as height and hair color are different from another
      person's body traits. Genetic differences can also affect the way a medication works in the
      body or the way two medications interact in the body. The purpose of this clinical study is
      to determine if a person's genetic make-up affects the way darunavir and ritonavir interact
      with pravastatin in the body.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">September 2010</completion_date>
  <primary_completion_date type="Actual">October 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Relative Change in Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
    <description>AUC of pravastatin when administered with darunavir/ritonavir divided by AUC of pravastatin when administered alone. The AUC was measured over a 24-hour dosing interval.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Relative Change in Pravastatin Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
    <description>Cmax of pravastatin when administered with darunavir/ritonavir divided by the Cmax of pravastatin when administered alone.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pravastatin Alone: Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
    <description>Dosing interval of 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pravastatin Alone: Pravastatin Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pravastatin + Darunavir/Ritonavir: Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
    <description>Dosing interval of 24 hours</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pravastatin + Darunavir/Ritonavir: Pravastatin Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Darunavir Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 8, 12 hours post-dose</time_frame>
    <description>AUC of darunavir over a 12-hour dosing interval.</description>
  </other_outcome>
  <other_outcome>
    <measure>Darunavir Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 8, 12 hours post-dose</time_frame>
    <description>Cmax of darunavir over a 12-hour dosing interval</description>
  </other_outcome>
  <other_outcome>
    <measure>Ritonavir Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</measure>
    <time_frame>0, 1, 2, 3, 4, 5, 6, 8, 12 hours post-dose</time_frame>
    <description>AUC of ritonavir over a 12-hour dosing interval.</description>
  </other_outcome>
  <other_outcome>
    <measure>Ritonavir Maximum Plasma Concentration (Cmax)</measure>
    <time_frame>0,1, 2, 3, 4, 5, 6, 8, 12 hours post-dose</time_frame>
    <description>Cmax of ritonavir over a 12-hour dosing interval</description>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">32</enrollment>
  <condition>HIV Infections</condition>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>SLCO1B1 Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with the SLCO1B1 *1A/*1A diplotype; Interventions: pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLCO1B1 Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants with the SLCO1B1 *1A/*1B or *1B/*1B diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SLCO1B1 Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who carry at least one SLCO1B1 *5, *15, or *17 diplotype; Interventions: Pravastatin 40 mg by mouth once daily on days 1-4, washout on days 5-11, darunavir 600 mg and ritonavir 100 mg by mouth twice daily on days 12-18, pravastatin 40 mg by mouth once daily on days 15-18.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Pravastatin 40 mg by mouth daily on days 1-4</description>
    <arm_group_label>SLCO1B1 Group 1</arm_group_label>
    <arm_group_label>SLCO1B1 Group 2</arm_group_label>
    <arm_group_label>SLCO1B1 Group 3</arm_group_label>
    <other_name>Pravachol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Darunavir</intervention_name>
    <description>Darunavir 600mg by mouth twice daily on days 12-18</description>
    <arm_group_label>SLCO1B1 Group 1</arm_group_label>
    <arm_group_label>SLCO1B1 Group 2</arm_group_label>
    <arm_group_label>SLCO1B1 Group 3</arm_group_label>
    <other_name>Prezista</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ritonavir</intervention_name>
    <description>Ritonavir 100mg by mouth twice daily on days 12-18</description>
    <arm_group_label>SLCO1B1 Group 1</arm_group_label>
    <arm_group_label>SLCO1B1 Group 2</arm_group_label>
    <arm_group_label>SLCO1B1 Group 3</arm_group_label>
    <other_name>Norvir</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pravastatin</intervention_name>
    <description>Pravastatin 40 mg by mouth daily on days 15-18</description>
    <arm_group_label>SLCO1B1 Group 1</arm_group_label>
    <arm_group_label>SLCO1B1 Group 2</arm_group_label>
    <arm_group_label>SLCO1B1 Group 3</arm_group_label>
    <other_name>Pravachol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Washout</intervention_name>
    <description>Washout (no medication) on days 5-11.</description>
    <arm_group_label>SLCO1B1 Group 1</arm_group_label>
    <arm_group_label>SLCO1B1 Group 2</arm_group_label>
    <arm_group_label>SLCO1B1 Group 3</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy, HIV-negative volunteers

        Exclusion Criteria:

          -  Currently active or chronic cardiovascular, hepatic, renal, pancreatic,
             gastrointestinal, neurologic, hematologic, psychiatric, metabolic, respiratory,
             inflammatory, or infectious disease

          -  Chronic pancreatitis

          -  History of rhabdomyolysis

          -  History of statin-associated myopathy

          -  Active malignancy

          -  History of significant skin disease, food allergy, drug allergy, dermatitis, eczema,
             psoriasis

          -  Pregnancy/breastfeeding

          -  HIV positive and/or AIDS

          -  serum creatinine grade 1 or greater (≥ 1.1 x upper limit of laboratory normal range
             [ULN]);

          -  hemoglobin grade 1 or greater (≤ 10.9 g/dL);

          -  platelet count grade 1 or greater (≤ 124.999 x 109/L);

          -  absolute neutrophil count grade 1 or greater (≤ 1.3 x 109/L);

          -  aspartate aminotransferase (AST) or alanine aminotransferase (ALT) grade 1 or greater
             (≥ 1.25 x ULN);

          -  total bilirubin grade 1 or greater (≥ 1.1 x ULN)

          -  serum lipase grade 1 or greater (≥ 1.1 x ULN)

          -  serum amylase grade 1 or greater (≥ 1.1 x ULN)

          -  any other laboratory abnormality of grade 2 or above
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christina L Aquilante, PharmD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Colorado, Denver</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado Denver</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 28, 2008</study_first_submitted>
  <study_first_submitted_qc>March 6, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2008</study_first_posted>
  <results_first_submitted>September 12, 2011</results_first_submitted>
  <results_first_submitted_qc>October 15, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 15, 2012</results_first_posted>
  <last_update_submitted>May 20, 2014</last_update_submitted>
  <last_update_submitted_qc>May 20, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 22, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>Pravastatin</keyword>
  <keyword>Darunavir</keyword>
  <keyword>Ritonavir</keyword>
  <keyword>Genetic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Hyperlipidemias</mesh_term>
    <mesh_term>Hyperlipoproteinemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Darunavir</mesh_term>
    <mesh_term>Pravastatin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Healthy volunteers were recruited from the Denver metro area between March 2008 and September 2009.</recruitment_details>
      <pre_assignment_details>Participants were genetically screened for solute carrier organic anion transporter family, member 1B1 (SLCO1B1) diplotypes as follows: Group 1, *1A/*1A (reference diplotype); Group 2, *1A/*1B or *1B/*1B diplotypes; and Group 3, subjects with at least one copy of the *5, *15, or *17 haplotype.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>SLCO1B1 Group 1</title>
          <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
        </group>
        <group group_id="P2">
          <title>SLCO1B1 Group 2</title>
          <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18.</description>
        </group>
        <group group_id="P3">
          <title>SLCO1B1 Group 3</title>
          <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="13"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="12"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>SLCO1B1 Group 1</title>
          <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
        </group>
        <group group_id="B2">
          <title>SLCO1B1 Group 2</title>
          <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
        </group>
        <group group_id="B3">
          <title>SLCO1B1 Group 3</title>
          <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="12"/>
            <count group_id="B3" value="7"/>
            <count group_id="B4" value="28"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="36" spread="11"/>
                    <measurement group_id="B2" value="37" spread="12"/>
                    <measurement group_id="B3" value="39" spread="11"/>
                    <measurement group_id="B4" value="36" spread="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Relative Change in Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
        <description>AUC of pravastatin when administered with darunavir/ritonavir divided by AUC of pravastatin when administered alone. The AUC was measured over a 24-hour dosing interval.</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1*1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
          <description>AUC of pravastatin when administered with darunavir/ritonavir divided by AUC of pravastatin when administered alone. The AUC was measured over a 24-hour dosing interval.</description>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.09" lower_limit="0.73" upper_limit="1.46"/>
                    <measurement group_id="O2" value="1.59" lower_limit="0.83" upper_limit="2.36"/>
                    <measurement group_id="O3" value="1.75" lower_limit="0.52" upper_limit="2.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Relative change data were compared between SLCO1B1 diplotype groups using one-way ANOVA (with post-hoc Bonferroni tests).</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.43</p_value>
            <p_value_desc>Threshold of significance was P&lt;0.05.</p_value_desc>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Relative Change in Pravastatin Maximum Plasma Concentration (Cmax)</title>
        <description>Cmax of pravastatin when administered with darunavir/ritonavir divided by the Cmax of pravastatin when administered alone.</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Relative Change in Pravastatin Maximum Plasma Concentration (Cmax)</title>
          <description>Cmax of pravastatin when administered with darunavir/ritonavir divided by the Cmax of pravastatin when administered alone.</description>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.11" lower_limit="0.69" upper_limit="1.53"/>
                    <measurement group_id="O2" value="1.69" lower_limit="0.83" upper_limit="2.55"/>
                    <measurement group_id="O3" value="2.32" lower_limit="0.24" upper_limit="4.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.28</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Darunavir Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
        <description>AUC of darunavir over a 12-hour dosing interval.</description>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 8, 12 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Darunavir Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
          <description>AUC of darunavir over a 12-hour dosing interval.</description>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58552" spread="29442"/>
                    <measurement group_id="O2" value="63679" spread="16985"/>
                    <measurement group_id="O3" value="60156" spread="13909"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.66</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Darunavir Maximum Plasma Concentration (Cmax)</title>
        <description>Cmax of darunavir over a 12-hour dosing interval</description>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 8, 12 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Darunavir Maximum Plasma Concentration (Cmax)</title>
          <description>Cmax of darunavir over a 12-hour dosing interval</description>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7770" spread="3483"/>
                    <measurement group_id="O2" value="8047" spread="2023"/>
                    <measurement group_id="O3" value="7789" spread="1467"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.85</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ritonavir Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
        <description>AUC of ritonavir over a 12-hour dosing interval.</description>
        <time_frame>0, 1, 2, 3, 4, 5, 6, 8, 12 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Ritonavir Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
          <description>AUC of ritonavir over a 12-hour dosing interval.</description>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng*hr/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5239" spread="3835"/>
                    <measurement group_id="O2" value="7178" spread="3520"/>
                    <measurement group_id="O3" value="7907" spread="3618"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.11</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Ritonavir Maximum Plasma Concentration (Cmax)</title>
        <description>Cmax of ritonavir over a 12-hour dosing interval</description>
        <time_frame>0,1, 2, 3, 4, 5, 6, 8, 12 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Ritonavir Maximum Plasma Concentration (Cmax)</title>
          <description>Cmax of ritonavir over a 12-hour dosing interval</description>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="844" spread="708"/>
                    <measurement group_id="O2" value="1143" spread="649"/>
                    <measurement group_id="O3" value="1279" spread="748"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.15</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pravastatin Alone: Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
        <description>Dosing interval of 24 hours</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18.</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Pravastatin Alone: Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
          <description>Dosing interval of 24 hours</description>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="63" spread="25.2"/>
                    <measurement group_id="O2" value="86.6" spread="36.3"/>
                    <measurement group_id="O3" value="123.4" spread="80.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.22</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pravastatin Alone: Pravastatin Maximum Plasma Concentration (Cmax)</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18.</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Pravastatin Alone: Pravastatin Maximum Plasma Concentration (Cmax)</title>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.7" spread="15.4"/>
                    <measurement group_id="O2" value="33.3" spread="17.1"/>
                    <measurement group_id="O3" value="46.2" spread="38.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.67</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pravastatin + Darunavir/Ritonavir: Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
        <description>Dosing interval of 24 hours</description>
        <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18.</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Pravastatin + Darunavir/Ritonavir: Pravastatin Area Under the Plasma Concentration-time Curve (AUC) Over the Dosing Interval</title>
          <description>Dosing interval of 24 hours</description>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng*h/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.4" spread="37.3"/>
                    <measurement group_id="O2" value="106.8" spread="47.9"/>
                    <measurement group_id="O3" value="145.7" spread="36.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.006</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pravastatin + Darunavir/Ritonavir: Pravastatin Maximum Plasma Concentration (Cmax)</title>
        <time_frame>0, 0.5, 1, 2, 3, 4, 6, 8, 12, 16, 20, 24 hours post-dose</time_frame>
        <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
        <group_list>
          <group group_id="O1">
            <title>SLCO1B1 Group 1</title>
            <description>SLCO1B1 *1A/*1A diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
          <group group_id="O2">
            <title>SLCO1B1 Group 2</title>
            <description>SLCO1B1 *1A/*1B or *1B/*1B diplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18.</description>
          </group>
          <group group_id="O3">
            <title>SLCO1B1 Group 3</title>
            <description>Carriers of at least one SLCO1B1 *5, *15, or *17 haplotype; Pravastatin 40 mg by mouth daily on days 1-4, washout on days 5-11, darunavir/ritonavir 600/100 mg by mouth twice daily on days 12-18, with pravastatin 40 mg added back on days 15-18</description>
          </group>
        </group_list>
        <measure>
          <title>Pravastatin + Darunavir/Ritonavir: Pravastatin Maximum Plasma Concentration (Cmax)</title>
          <population>The population analyzed included participants who completed the pravastatin alone phase and the pravastatin + darunavir/ritonavir phase of the study.</population>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="12"/>
                <count group_id="O3" value="7"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.1" spread="19.7"/>
                    <measurement group_id="O2" value="42.4" spread="23.0"/>
                    <measurement group_id="O3" value="52.8" spread="11.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.08</p_value>
            <method>ANOVA</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Pravastatin Alone</title>
          <description>Pravastatin 40 mg by mouth daily on days 1-4; Includes 32 participants who received at least one dose of pravastatin 40 mg during days 1-4.</description>
        </group>
        <group group_id="E2">
          <title>Darunavir/Ritonavir Alone</title>
          <description>Darunavir/Ritonavir 600/100 mg by mouth twice daily on days 12-14; Includes 31 participants who received at least one dose of darunavir/ritonavir during days 12-14.</description>
        </group>
        <group group_id="E3">
          <title>Pravastatin + Darunavir/Ritonavir</title>
          <description>Darunavir/ritonavir 600/100 mg by mouth twice daily and pravastatin 40 mg by mouth once daily on days 15-18. Includes 28 participants who received at least one dose of darunavir/ritonavir and pravastatin during days 15-18.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Angioedema</sub_title>
                <description>1 patient experienced grade 2 angioedema (as described by DAIDS criteria). This was not technically SAE, but did require pharmacologic intervention to prevent a more serious reaction.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="32"/>
                <counts group_id="E2" subjects_affected="22" subjects_at_risk="31"/>
                <counts group_id="E3" subjects_affected="18" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Nausea/Vomiting/Dyspepsia/Abdominal Pain</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="31"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" events="13" subjects_affected="13" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="31"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Hypoalbuminemia</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="28"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Muscle pain</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="28"/>
              </event>
              <event>
                <sub_title>Shoulder/Neck Pain</sub_title>
                <description>Grade 1 per DAIDS criteria.</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="31"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="28"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Prior to publication or presentation, the PI will provide the sponsor with at least 60 days for review of a manuscript</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The study included only heterozygous carriers of the SLCO1B1 *15 and *17 haplotypes. Pravastatin urine concentrations were not measured; therefore the impact of darunavir/ritonavir on pravastatin renal clearance was not assessed in this population.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Christina Aquilante, Pharm.D.</name_or_title>
      <organization>University of Colorado Denver</organization>
      <phone>303-724-6126</phone>
      <email>christina.aquilante@ucdenver.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

